Evidence Based This post has 26 references
1

CYP3A5 Enzyme: Roles and Genetic Variants

Written by Biljana Novkovic, PhD | Last updated:
Puya Yazdi
Medically reviewed by
Puya Yazdi, MD | Written by Biljana Novkovic, PhD | Last updated:

SelfHacked has the strictest sourcing guidelines in the health industry and we almost exclusively link to medically peer-reviewed studies, usually on PubMed. We believe that the most accurate information is found directly in the scientific source.

We are dedicated to providing the most scientifically valid, unbiased, and comprehensive information on any given topic.

Our team comprises of trained MDs, PhDs, pharmacists, qualified scientists, and certified health and wellness specialists.

All of our content is written by scientists and people with a strong science background.

Our science team is put through the strictest vetting process in the health industry and we often reject applicants who have written articles for many of the largest health websites that are deemed trustworthy. Our science team must pass long technical science tests, difficult logical reasoning and reading comprehension tests. They are continually monitored by our internal peer-review process and if we see anyone making material science errors, we don't let them write for us again.

Our goal is to not have a single piece of inaccurate information on this website. If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please leave a comment or contact us at [email protected]

Note that each number in parentheses [1, 2, 3, etc.] is a clickable link to peer-reviewed scientific studies. A plus sign next to the number “[1+, 2+, etc...]” means that the information is found within the full scientific study rather than the abstract.

//

CYP3A5 shares many similarities with CYP3A4. This means it may participate in the clearance of over 50% of clinically used drugs. However, a striking fact related to this enzyme is that many people actually don’t have it. Read on to learn more about the roles and gene variants of this enzyme, and how they affect drug metabolism.

What is CYP3A5?

CYP3A5 is one of the cytochrome P450 monooxygenases (CYPs). These are enzymes that eliminate most of the drugs and toxins from the human body [1].

Function

This enzyme is very similar in structure and function to CYP3A4. However, unlike CYP3A4, its activity varies greatly between people, and many actually don’t have a functional version of this enzyme [2].

The enzyme is functional in most Africans but in few Whites [2].

In people who do have this enzyme, it can represent over 50% of the total liver CYP3A activity [3].

This enzyme metabolizes:

  • Antihypertensive drugs: felodipine [4] and nifedipine [5].
  • Immune suppressants: sirolimus [6], tacrolimus [7, 8] and cyclosporine A [9].
  • Antiemetics: granisetron [10].
  • Anticancer drugs: lapatinib [11] and vincristine [12].
  • TNF inhibitors: etanercept [13].
  • Cholesterol-lowering drugs: simvastatin and atorvastatin [14]
  • Sedatives midazolam and alprazolam (Xanax) [5].
  • Antibiotic erythromycin [5].
  • Antiretroviral drugs: saquinavir [9].

Location

This enzyme is found in various tissues, especially the liver, kidney, and lungs [3, 15].

It plays an important function in the kidneys and may be related to blood pressure [15].

Roles in Health

This enzyme may act as a tumor suppressor. Lower enzyme levels may be associated with more aggressive hepatocellular carcinoma (liver cancer), quicker disease recurrence after treatment, and worse overall patient survival [16].

Roles in Disease

This enzyme may promote prostate cancer cell growth. In a study of 873 Japanese women, those with the functional enzyme had higher rates of breast cancer [9, 17].

In a trial of 385 subjects, a nonfunctional enzyme variant was associated with higher rates of acute and chronic leukemia [18].

Genetics

It’s important to note that just because certain genotypes are associated with a condition or irregular lab marker, it doesn’t necessarily mean that everyone with that genotype will actually develop the condition. Many different factors, including other genetic and environmental factors, can influence the risk of conditions described below.

There are over 25 variants of this enzyme, but many of them are nonfunctional. The fully functional variant is known as the CYP3A5*1 [9].

The frequency of the functional variant is substantially different across ethnic groups. The functional enzyme is found in 45–94% of subjects of African descent, 8–15% of Whites and 23–40% of Asians [15, 2].

Only individuals with at least one CYP3A5*1 have large amounts of the enzyme. They metabolize some CYP3A substrates more rapidly than do people without this enzyme [3, 9].

In two studies of over 1,000 subjects, those with the functional variant were more susceptible to salt-sensitive hypertension (elevated blood pressure) [19, 20].

Some CYP3A5*1 carriers tend to reabsorb more sodium in the kidneys as they get older [15].

Enhanced kidney sodium re-absorption could have an advantage in equatorial populations experiencing water shortages. This may explain why this variation is correlated with the geographical distance from the equator [15].

CYP3A5*1 was associated with lower blood pressure in Europeans, but higher blood pressure in Africans [15, 9].

In a study of 873 Japanese women, those with the functional enzyme had higher rates of breast cancer [9].

  • RS776746

Rs776746 is the most common non-functional variant of the enzyme, designated as CYP3A5*3 [9].

Its frequency ranges from 14% among sub-Saharan Africans to over 95% in European populations [21, 9].

According to a meta-analysis of 17 studies and over 14,500 participants, This variant correlates with higher rates of acute leukemia (ALL), chronic leukemia (CML), and colorectal cancer, especially among Asian and Caucasian populations [22].

In a study of 64 children, those with rs776746 had improved asthma control [23].

  • RS10264272

Rs10264272 is another nonfunctional variant. It is frequent in Africans (7-17%), but rare or absent in Europeans and Asians [21, 9].

Other:

Factors That Increase/Decrease CYP3A5

It is likely that the compounds and factors that increase or decrease CYP3A4 have the same effect on CYP3A5. However, compared to CYP3A4, a lot less research has been carried out testing CYP3A5. Preliminary studies that include this enzyme are listed below.

The clinical relevance of changing the activity of this enzyme is not fully understood. In theory, it may impact the safety and efficacy of drugs metabolized by CYP3A5.

These may increase CYP3A5:

These decrease CYP3A5:

About the Author

Biljana Novkovic

Biljana Novkovic

PhD
Biljana received her PhD from Hokkaido University.
Before joining SelfHacked, she was a research scientist with extensive field and laboratory experience. She spent 4 years reviewing the scientific literature on supplements, lab tests and other areas of health sciences. She is passionate about releasing the most accurate science and health information available on topics, and she's meticulous when writing and reviewing articles to make sure the science is sound. She believes that SelfHacked has the best science that is also layperson-friendly on the web.

Click here to subscribe

RATE THIS ARTICLE

1 Star2 Stars3 Stars4 Stars5 Stars
(1 votes, average: 5.00 out of 5)
Loading...

FDA Compliance

The information on this website has not been evaluated by the Food & Drug Administration or any other medical body. We do not aim to diagnose, treat, cure or prevent any illness or disease. Information is shared for educational purposes only. You must consult your doctor before acting on any content on this website, especially if you are pregnant, nursing, taking medication, or have a medical condition.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.